Write your message
Volume 1, Issue 1 (5-2015)                   IJCA 2015, 1(1): 1-6 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Otukesh H, Sayyahfar S, Hoseini R, Rahimzadeh N, Jafari M, Moradi Y. Antiviral agents for preventing cytomegalovirus infection in pediatric renal transplant recipients: A systematic review. IJCA 2015; 1 (1) :1-6
URL: http://ijca.iums.ac.ir/article-1-21-en.html
Abstract:   (2370 Views)

Background and Objective: Cytomegalovirus (CMV) infections are associated with severe morbidity and mortality in patients, especially pediatric renal transplantation patients. The use of immunosuppressive agents places these patients at the risk of viral infections. As cytomegalovirus infection influences the graft outcome, adopting useful strategies for limiting this virus after transplantation seems necessary.

MethodsThis systematic review evaluates all articles about the prophylactic treatment in pediatric renal graft recipients.

ResultsThere are several anti-viral agents that are used alone or in combination for preventing CMV infection. The prophylactic agents that are used in pediatric recipients include CMV-Ig, IVIG, acyclovir/valacyclovir, and ganciclovir/valganciclovir. CMV-Ig is an adjective agent and it is less effective if used alone.  Although performed studies in children are not sufficient to determine valacyclovir effect in preventing reactivation of cytomegalovirus, valacyclovir is used in moderate risk recipients for CMV infection. It seems that valacyclovir is less effective than valganciclovir.

ConclusionNowadays oral valganciclovir is the most appropriate prophylactic agent used in most transplant centers for children and adults.  However it appears that valganciclovir prevents cytomegalovirus infection only during prophylaxis period. The incidence of late CMV infection does not reduce by this drug. Some trials in adults and a retrospective study in children recommend that longer duration of prophylaxis with valganciclovir lowers the incidence of CMV infection in late stage.

Full-Text [PDF 365 kb]   (1129 Downloads)    
Type of Study: Original Research |

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | International Journal of Children and Adolescents

Designed & Developed by : Yektaweb